Kyowa Hakko Kirin and Syndax sign agreement to develop entinostat in Japan and Korea

[News]

Kyowa Hakko Kirin Co., Ltd., (Headquarters: Chiyoda-ku, Tokyo; president and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") and Syndax Pharmaceuticals, Inc., (Waltham, Mass.; president and CEO: Arlene M. Morris, "Syndax") today jointly announced that the companies have entered into a license agreement for the exclusive rights to develop and commercialize entinostat in Japan and Korea.

More... (http://www.news-medical.net/news/20150107/Kyowa-Hakko-Kirin-and-Syndax-sign-agreement-to-develop-entinostat-in-Japan-and-Korea.aspx)